Biotechnology
Compare Stocks
2 / 10Stock Comparison
ALEC vs AVXL
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
ALEC vs AVXL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $269M | $289M |
| Revenue (TTM) | $21M | $0.00 |
| Net Income (TTM) | $-143M | $-40M |
| Operating Margin | -7.4% | — |
| Total Debt | $36M | $0.00 |
| Cash & Equiv. | $66M | $103M |
ALEC vs AVXL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Alector, Inc. (ALEC) | 100 | 7.5 | -92.5% |
| Anavex Life Science… (AVXL) | 100 | 75.9 | -24.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALEC vs AVXL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ALEC is the clearest fit if your priority is momentum.
- +139.2% vs AVXL's -63.2%
AVXL carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.51
- EPS growth -3.8%
- -25.7% 10Y total return vs ALEC's -86.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -34.9% revenue growth vs ALEC's -79.1% | |
| Quality / Margins | 4.5% margin vs ALEC's -6.8% | |
| Stability / Safety | Beta 1.51 vs ALEC's 2.47 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +139.2% vs AVXL's -63.2% | |
| Efficiency (ROA) | -30.0% ROA vs ALEC's -48.7% |
ALEC vs AVXL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ALEC vs AVXL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
AVXL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ALEC and AVXL operate at a comparable scale, with $21M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $21M | $0 |
| EBITDAEarnings before interest/tax | -$156M | -$30M |
| Net IncomeAfter-tax profit | -$143M | -$40M |
| Free Cash FlowCash after capex | -$184M | -$34M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | -7.4% | — |
| Net MarginNet income ÷ Revenue | -6.8% | — |
| FCF MarginFCF ÷ Revenue | -8.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -88.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -15.1% | +54.4% |
Valuation Metrics
AVXL leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $269M | $289M |
| Enterprise ValueMkt cap + debt − cash | $240M | $187M |
| Trailing P/EPrice ÷ TTM EPS | -1.76x | -5.78x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 12.80x | — |
| Price / BookPrice ÷ Book value/share | 8.20x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AVXL leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
AVXL delivers a -31.5% return on equity — every $100 of shareholder capital generates $-32 in annual profit, vs $-5 for ALEC. On the Piotroski fundamental quality scale (0–9), AVXL scores 2/9 vs ALEC's 1/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -4.7% | -31.5% |
| ROA (TTM)Return on assets | -48.7% | -30.0% |
| ROICReturn on invested capital | -170.3% | — |
| ROCEReturn on capital employed | -55.0% | -47.8% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 1.18x | — |
| Net DebtTotal debt minus cash | -$30M | -$103M |
| Cash & Equiv.Liquid assets | $66M | $103M |
| Total DebtShort + long-term debt | $36M | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
AVXL leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AVXL five years ago would be worth $2,759 today (with dividends reinvested), compared to $1,492 for ALEC. Over the past 12 months, ALEC leads with a +139.2% total return vs AVXL's -63.2%. The 3-year compound annual growth rate (CAGR) favors AVXL at -28.1% vs ALEC's -32.5% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +59.5% | -15.2% |
| 1-Year ReturnPast 12 months | +139.2% | -63.2% |
| 3-Year ReturnCumulative with dividends | -69.2% | -62.9% |
| 5-Year ReturnCumulative with dividends | -85.1% | -72.4% |
| 10-Year ReturnCumulative with dividends | -86.4% | -25.7% |
| CAGR (3Y)Annualised 3-year return | -32.5% | -28.1% |
Risk & Volatility
Evenly matched — ALEC and AVXL each lead in 1 of 2 comparable metrics.
Risk & Volatility
AVXL is the less volatile stock with a 1.51 beta — it tends to amplify market swings less than ALEC's 2.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALEC currently trades 71.8% from its 52-week high vs AVXL's 22.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.47x | 1.51x |
| 52-Week HighHighest price in past year | $3.40 | $13.99 |
| 52-Week LowLowest price in past year | $0.97 | $2.61 |
| % of 52W HighCurrent price vs 52-week peak | +71.8% | +22.3% |
| RSI (14)Momentum oscillator 0–100 | 59.1 | 47.0 |
| Avg Volume (50D)Average daily shares traded | 684K | 1.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ALEC as "Buy" and AVXL as "Buy". Consensus price targets imply 252.6% upside for AVXL (target: $11) vs 43.4% for ALEC (target: $4).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $3.50 | $11.00 |
| # AnalystsCovering analysts | 14 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
AVXL leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
ALEC vs AVXL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ALEC or AVXL a better buy right now?
Analysts rate Alector, Inc.
(ALEC) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ALEC or AVXL?
Over the past 5 years, Anavex Life Sciences Corp.
(AVXL) delivered a total return of -72. 4%, compared to -85. 1% for Alector, Inc. (ALEC). Over 10 years, the gap is even starker: AVXL returned -25. 7% versus ALEC's -86. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ALEC or AVXL?
By beta (market sensitivity over 5 years), Anavex Life Sciences Corp.
(AVXL) is the lower-risk stock at 1. 51β versus Alector, Inc. 's 2. 47β — meaning ALEC is approximately 64% more volatile than AVXL relative to the S&P 500.
04Which is growing faster — ALEC or AVXL?
On earnings-per-share growth, the picture is similar: Anavex Life Sciences Corp.
grew EPS -3. 8% year-over-year, compared to -13. 0% for Alector, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ALEC or AVXL?
Anavex Life Sciences Corp.
(AVXL) is the more profitable company, earning 0. 0% net margin versus -679. 2% for Alector, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVXL leads at 0. 0% versus -741. 3% for ALEC. At the gross margin level — before operating expenses — ALEC leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ALEC or AVXL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ALEC or AVXL better for a retirement portfolio?
For long-horizon retirement investors, Anavex Life Sciences Corp.
(AVXL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Alector, Inc. (ALEC) carries a higher beta of 2. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AVXL: -25. 7%, ALEC: -86. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ALEC and AVXL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.